Test of a lung cancer prognosis kit after early tumor removal
Part of Cancer, Lungs & breathing clinical trials.
This study tests a lab “prognosis kit” to better predict how early-stage lung cancer may progress after the tumor has been fully removed. You may be asked to provide tumor samples and possibly blood/body fluid samples so researchers can validate the kit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years old or older and can sign consent to join the study.
- Your lung cancer diagnosis is lung adenocarcinoma confirmed by tumor pathology.
- After surgery, your lung cancer stage is IA, IB, II, or IIIA (and it must be the correct stage after surgery).
- Your surgery removed the tumor completely with clear margins (R0 resection).
- Your general health/function is good (ECOG performance status 0 or 1, as judged by the study team).
- You are willing to share samples: tumor tissue or cytology, plus blood and possibly certain body fluids (for follow-up/recurrence).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to predict if non-small cell lung cancer will return after surgery. You will give blood samples to look for cancer cells, and the team will build a model to help plan better follow-up care.
This study follows people with stage I lung cancer to see how they do after surgery. It aims to learn what affects recovery and long-term outcomes.
This study is testing whether certain markers in your blood or tissue can help find lung cancer early. It is for people who have lung cancer that can be removed by surgery and haven't had treatment yet.
This study looks at how well your lungs work after surgery for lung cancer. It uses special scans and breathing tests to help doctors better predict your recovery.
This trial uses your tumor sample to guide personalized treatment decisions for certain lung cancers. It may help by matching you to a more targeted plan based on genetic testing and your prior treatment history.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.